Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Daniel J. Lenihan, Teresa López‐Fernández et al.|European Journal of Heart Failure|2020Cited by 767
Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac AmyloidosisMarianna Fontana, James Moon, Silvia Pica et al.|Circulation|2015Cited by 610
Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 YearsAdam Ioannou, Marianna Fontana, Rishi Patel et al.|Circulation|2022Cited by 226
[11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trialXilin Wu, Morris J. Brown, Russell Senanayake et al.|Nature Medicine|2023Cited by 137
Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosisRishi Patel, Marianna Fontana, Adam Ioannou et al.|European Journal of Heart Failure|2022Cited by 94